Taysha Gene Therapies Stock Forecast

Stock Price Forecast

According to 12 analysts polled by S&P Global, Taysha Gene Therapies stock has a consensus rating of "Strong Buy" and an average price target of $13.25. The average 1-year stock price forecast is 108.01% higher than the current stock price, while the lowest is $10 (+56.99%) and the highest is $19 (+198.27%).

Price Target: $13.25 (+108.01%)

Analyst Consensus: Strong Buy

Price Target

Chart

Target	Low	Average	Median	High
Price	$10	$13.25	$12.5	$19
Change	+56.99%	+108.01%	+96.23%	+198.27%

Analyst Ratings

The average analyst rating for Taysha Gene Therapies stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart

Rating	Mar '26	Apr '26	May '26	Jun '26	Jul '26	Aug '26
Strong Buy	11	11	10	10	9	9
Buy	3	3	3	3	3	3
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	14	14	13	13	12	12

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Salveen Richter Goldman Sachs	Goldman Sachs	Buy Maintains $11 → $13	Buy	Maintains	$11 → $13	+104.08%	Jul 21, 2026
Evan Seigerman BMO Capital	BMO Capital	Buy Maintains $14	Buy	Maintains	$14	+119.78%	Jul 1, 2026
Gil Blum Needham	Needham	Buy Maintains $12	Buy	Maintains	$12	+88.38%	Jun 30, 2026
Biren Amin Piper Sandler	Piper Sandler	Buy Maintains $12	Buy	Maintains	$12	+88.38%	Jun 30, 2026
Jack Allen Robert W. Baird	Robert W. Baird	Buy Maintains $12 → $15	Buy	Maintains	$12 → $15	+135.48%	Jun 30, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

2.00M

from 9.77M

-79.54%

from 9.77M

Revenue Next Year

29.72M

from 2.00M

1,386.10%

from 2.00M

EPS This Year

-0.44

from -0.32

EPS Next Year

-0.44

from -0.44

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	-	2.50M	15.45M	8.33M	9.77M	2.00M
Revenue Growth	-	-	517.55%	-46.07%	17.28%	-79.54%
Operating Income	-173.27M	-126.03M	-71.37M	-86.62M	-110.50M	-177.85M
Net Income	-174.52M	-166.01M	-111.57M	-89.30M	-109.00M	-172.50M
EPS	-	-	-	-	-0.32	-0.44
Free Cash Flow	-71.32M	-75.31M	-68.51M	-48.15M	-56.70M	-155.31M
No. Analysts	-	-	-	-	-	12

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Chart

Revenue	2026	2027	2028
High	15.0M
Avg	2.0M
Low	n/a

Revenue Growth

Chart

Revenue Growth	2026	2027	2028
High	53.5%
Avg	-79.5%
Low	-100.0%

EPS Forecast

Chart

EPS	2026	2027	2028
High	-0.36
Avg	-0.44
Low	-0.54

EPS Growth

Chart

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-